Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Investor Presentation (November 2023)
37 slides from Day One Biopharmaceuticals's investor presentation, Nov 17, 2023

Slide 1: Day One Biopharmaceuticals: Targeted Therapies for People of All Ages
Exhibit 99.2 Day One Biopharmaceuticals Targeted Therapies for People of All Ages November 2023

Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

Slide 3: Cancer Drug Development For People Of All Ages
Cancer Drug Development For People Of All Ages A Mission That Creates Value • Develop medicines for genomically-defined cancers • Establish first-in-class position through rapid registration pathways • Expand to adolescent and adult populations in parallel and pursue those opportunities with the sam

Slide 4: Our Pipeline
Our Pipeline Recent & Anticipated Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Milestones Tovorafenib (DAY101) FDA acceptance of NDA: October 2023 Type II RAF Inhibitor PDUFA target action date: 1 Relapsed pLGG FIREFLY-1 (pivotal) • FDA Breakthrough Therapy April 30, 2024 Designa

Slide 5: Tovorafenib (DAY101) Type II RAF Inhibitor
Tovorafenib (DAY101) Type II RAF Inhibitor

Slide 6: Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children
Pediatric Low-Grade Glioma (pLGG): The Most Common Type Of Brain Tumor In Children PLGGs are chronic and relentless, with patients suffering profound tumor and 6 treatment-associated morbidity that can impact their life trajectory over the long term 7 A Serious and Life-Threatening Disease Disease S

Slide 7: Conventional Treatments Can Be Disruptive To Childhood
Conventional Treatments Can Be Disruptive To Childhood and Can Have Significant Long-Term Consequences Chemotherapy Radiation Surgery • Significant recovery times • Requirement for indwelling • Risk of secondary malignancy catheter and weekly • Risks of complications • Risk of malignant infusions tr

Slide 8: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations
Tovorafenib (DAY101) Inhibits Both BRAF Fusions And BRAF V600 Mutations • Tovorafenib (DAY101) is an investigational, MAPK pathway RAS-independent activation of the MAPK pathway oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both RAS monomeric and dimeric RAF kina

Slide 9: The Current pLGG Treatment Paradigm
The Current pLGG Treatment Paradigm Reflects The Unrelenting Nature Of This Chronic Brain Tumor 1L 2L 3L Presentation Surgical Intervention ~35% ~20% Targeted Tx Targeted Tx Targeted Tx GTR No Recurrence (5-10%) (40-50%) (40-50%) 1 Biopsy (>95%) Suspected ~65% ~50% ~50% pLGG ≤ Partial Eventual Addit

Slide 10: Pivotal Phase Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)
Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) In Relapsed Or Progressive pLGG (FIREFLY-1) – Fully Enrolled & Data Submitted to FDA Trial Design Endpoints (Pivotal Arm 1) 1 • Three arm, open-label, global registrational phase 2 trial • Primary endpoint: ORR based on RANO-HGG , assessed by

Slide 11: Data from Pivotal Phase FIREFLY-1 Trial
Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff

Slide 12: FIREFLY-1 Baseline Patient Characteristics
FIREFLY-1 Baseline Patient Characteristics Location (n=77) Arm 1 Characteristic (n=77) Deep midline structures 12% Optic pathway Median age, years (range) 8 (2-21) 51% Gender, n (%) Other Male 40 (52) † 16% Female 37 (48) Cerebral hemisphere Race, n (%) 8% Cerebellum White 41 (53) 6% Asian 5 (6) Bra

Slide 13: Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG
Tumor Response To Tovorafenib (DAY101) Using RAPNO-LGG, RANO-LGG and RANO-HGG RAPNO-LGG RAPNO-LGG RANO-LGG RANO-HGG Response (IRC) n=76 N=76 N=69 ORR,* n (%) 39 (51) 40 (53) 46 (67) 95% CI 40-63 41-64 54-78 CBR,* n (%) 62 (82) 63 (83) 64 (93) SD of any length of time 43 (57) 46 (61) 54 (78) SD ≥12 m

Slide 14: Duration Of Tovorafenib Therapy For Patients With RAPNO-LGG Evaluable Lesions
Duration Of Tovorafenib (DAY101) Therapy For All Patients With RAPNO-LGG Evaluable Lesions 5.3 Median time to response Months Median duration of 13.8 treatment Months Overall treatment duration (months) 14 June 5, 2023 data cutoff. Patients

Slide 15: Tumor Kinetics In Patients With Best Response Of Progressive Disease
Tumor Kinetics In Patients With Best Response Of Progressive Disease According To RAPNO-LGG The majority of patients who had radiographic progression by RAPNO-LGG at their initial disease assessment had subsequent prolonged reductions in the size of their tumor with continued treatment. Months 15 Ju

Slide 16: Tumor Response According To RAPNO-LGG In Subgroups
Tumor Response To Tovorafenib (DAY101) According to RAPNO-LGG In Subgroups Defined By Baseline Characteristics Male (n=40) Female (n=36) 6 months-<2 years of age (n=0) Analysis of response 2-<6 years of age (n=14) data across various 6-<12 years of age (n=40) subgroups shows no 12-<16 years of age (

Slide 17: Tumor Response Consistent Across BRAF Fusion And Mutation Patients
Tumor Response To Tovorafenib (DAY101) Across Three Assessment Criteria Were Consistent Across BRAF Fusion And Mutation Patients, and Patients With Prior MAPK Treatment 2 3,4 1 RAPNO-LGG RANO-LGG RANO-HGG Response (IRC) n n n ORR,* n (%) 76 39 (51) 76 40 (53) 69 46 (67) BRAF fusion 64 33 (52) 64 33

Slide 18: Tovorafenib Safety Data (n=137)
Tovorafenib (DAY101) Safety Data (n=137) TEAEs TRAEs Preferred Term, n (%) Any Grade Grade ≥3 Any Grade Grade ≥3 Any AE 137 (100) 86 (63) 134 (98) 58 (42) Hair color changes 104 (76) 0 104 (76) 0 • 9 patients (7%) had TRAEs Anemia 81 (59) 15 (11) 67 (49) 14 (10) leading to discontinuation Elevated C

Slide 19: Estimated BRAF-Altered pLGG Patient Population In The U.S.
Estimated BRAF-Altered pLGG Patient Population In The U.S. Estimated BRAF-Altered Patients in the U.S. • An estimated 26,000 children/young adults are living with BRAF-altered (BRAF fusions or BRAF 1-5 V600E mutations) pLGGs in the U.S. today • Despite significant disease burden, many pLGGs undergo

Slide 20: Key Takeaways From FIREFLY-1 Data And Next Steps
Key Takeaways From FIREFLY-1 Data And Next Steps • Clinically meaningful data from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusions or BRAF V600E mutations (“BRAF-altered”) • 51% ORR by RAPNO-LGG • 53% ORR by RANO-LGG • 67% ORR by RANO-HGG • Deepening of resp

Slide 21: FIREFLY-2/LOGGIC Pivotal Phase Trial in Frontline pLGG
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Frontline pLGG

Slide 22: FIREFLY-2/LOGGIC Pivotal Phase Trial Of Tovorafenib In Frontline pLGG
FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Frontline pLGG Trial Design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RANO-LGG criteria, assessed by blinded 1 (DAY101) vs SoC chemotherapy independent cen

Slide 23: FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib With Pimasertib
FIRELIGHT-1 Phase 1b/2 Trials Evaluating Tovorafenib (DAY101) as a Combination with Pimasertib

Slide 24: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor
Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors • Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 • Extensive non-clinical and clinical develo

Slide 25: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib
Vertical MAPK Pathway Inhibition With Tovorafenib (DAY101) And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors BRAF KRAS or NRAS non-V600 mutant mutant MEK RAF/ PI3K/m RAL MEK/ERK TOR ERK Proliferation, survival Proliferation, survival Type II RAFi + MEKI Type II RAFi + MEKi Type II R

Slide 26: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)
Tovorafenib (DAY101) / Pimasertib Combination In Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints 2 • Combination dose escalation, global phase 1b/2 trial • Phase 1b: PK, PD and Safety, MTD/RP2D • Phase 1b, BOIN (adaptive), n = 10/cohort (approximately) • Phase 2: Efficacy (ORR, DOR) • Phase 2, S

Slide 27: Summary
NZ Day One BIOPHARMACEUTICALS Summary

Slide 28: Financial Summary: DAWN
Financial Summary: DAWN Cash, cash equivalents and short-term investments ~87.0 million shares of common stock as of September 30, 2023: $405.5 million (no debt) outstanding as of November 1, 2023 Nine Months Ended Nine Months Ended $ Millions 9/30/23 9/30/22 R&D Expense $93.2 $59.6 G&A Expense $53.

Slide 29: Next Steps
Next Steps FIREFLY-1 • NDA in May 2023 • FDA acceptance of NDA and priority review granted in October 2023 • PDUFA target action date of April 30, 2024 • Data published in Nature Medicine and oral presentation at SNO in November 2023 FIREFLY-2 • Advance tovorafenib as a frontline therapy for patient

Slide 30: Appendix
Appendix `

Slide 31: Duration Of Tovorafenib Therapy For Patients With RANO-HGG Evaluable Lesions
Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions 3.0 Median time to response Months Median duration of 16.6 treatment Months Overall treatment duration (months) 31 June 5, 2023 data cutoff. Patients

Slide 32: Duration Of Tovorafenib Therapy For Patients With RANO-LGG Evaluable Lesions
Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-LGG Evaluable Lesions 5.5 Median time to response Months Median duration of 14.4 treatment Months Overall treatment duration (months) 32 June 5, 2023 data cutoff. Patients

Slide 33: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Optic Pathway Glioma
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis -36 6 Months -30 -24 -18 -12 -6 0 PR Diagnostic biopsy 3L: Tovorafen

Slide 34: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation Months -84 -72 -60 -48 -36 -24 -12 0 12 PR Suboccipital 2L: Carboplatin/vincristine cra

Slide 35: Case Study: Tovorafenib In BRAF V600E Mutation Deep Midline Astrocytoma
Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty Months -60 -48 -36 -24 -12 0 12 PR Subtotal 1L: Carboplatin/vincristine 2L: Dabrafenib 3L: Tovorafenib resect

Slide 36: Case Study: Tovorafenib In KIAA1549-BRAF Fusion Optic Pathway Glioma
Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma 8-year-old boy with relapsed pilomyxoid astrocytoma of the optic pathway, with visual loss in right eye, visual field loss in left eye, fatigue, intermittent nausea/vomiting, intermittent headaches, anorexia, a

Slide 37: FIREFLY-2/LOGGIC: Pivotal Phase Study In Newly Diagnosed pLGG
FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG • Collaboration between Day One and the Approximately 100 potential sites (~65 from the LOGGIC consortium) LOGGIC consortium, internationally recognized experts in pLGG research ‒ Coupled with the LOGGIC-CORE mol
Source: SEC EDGAR · 8-K filed Nov 17, 2023
More decks from Day One Biopharmaceuticals Inc
Investor Presentation (March 2026)43 slides · Mar 2, 2026
FY2025 Earnings Presentation20 slides · Feb 24, 2026
Q4 2025 Earnings Presentation43 slides · February 2026
Investor Presentation (January 2026)45 slides · Jan 12, 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)21 slides · Jan 12, 2026
Investor Presentation (January 2026)44 slides · Jan 6, 2026